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Cohort-Comparison of Thoracic Endovascular Aortic Repair with
Open Thoracic Aortic Repair Using Modern End-Organ
Preservation Strategies
Dean J. Arnaoutakis, George J. Arnaoutakis, Robert J. Beaulieu,
Christopher J. Abularrage, Ashish S. Shah, James H. Black III. The Johns
Hopkins Hospital, Baltimore, Md
Objectives: Pivotal trials showed that thoracic endovascular aortic
repair (TEVAR) has improved outcomes compared with open surgery for
treating descending thoracic aortic aneurysms. However, those trials
included historical open controls in which modern end-organ preservation
strategies were not routinely employed. In an effort to create a more level
assessment, we compared our outcomes of TEVAR with modern open
thoracic aortic repair (OTAR) controls.
Methods: A retrospective review of a prospective database of thoracic
aortic aneurysm patients undergoing TEVAR was compared with a contem-
poraneous cohort of OTAR patients. Partial bypass or hypothermic circula-
tory arrest (HCA) was used in all OTAR patients. Both groups underwent
cerebrospinal ﬂuid (CSF) drain placement when feasible. Preoperative char-
acteristics, operative variables, and outcomes were recorded, and the
Kaplan-Meier method was used for 1-year survival estimates. Subgroup
analysis was performed using length of aortic stent graft coverage or length
of aortic replacement.
Results: During the study period (2002-2013), 81 patients under-
went TEVAR and 61 underwent OTAR with median follow-up of 23.7
months (interquartile range, 6.7-55.1) and 36.4 months (interquartile
range, 9.6-60.2), respectively. TEVAR patients had signiﬁcantly lower 30-
day mortality (2.5% vs 13.1%; P ¼ .02) and fewer complications including
pneumonia (P ¼ .01) and rebleeding (P ¼ .03). However, there was no
difference in permanent spinal cord ischemia (SCI) (1% vs 2%; P ¼ .9) or
estimated 1-year survival (P ¼ .9). Among OTAR patients, HCA tended
to have higher 30-day mortality (16% vs 7%, P ¼ .43). Cox regression
revealed that advanced age and higher baseline creatinine levels were asso-
ciated with greater hazard of 1-year mortality; TEVAR and CSF drain place-
ment were protective of 1-year survival. For patients with <20 cm of aortic
stent graft or aortic graft replacement, there was no difference in 30-day
mortality (P ¼ .07) or permanent SCI (TEVAR n ¼ 0, 0% vs OTAR n ¼
1, 2%; P ¼ .9). For those with $20 cm of aortic stent graft or replacement,
there was no difference in 30-day mortality (P ¼ .9) or permanent SCI
(TEVAR n ¼ 1, 2% vs OTAR n ¼ 0, 0%; P ¼ .9).
Conclusions: TEVAR continues to show improved perioperative
outcomes with decreased 30-day mortality and fewer major adverse events
compared with OTAR. However, with the advent of routine end-organ
preservation during OTAR, SCI can be safely reduced to comparable levels
with those of TEVAR. Length of aortic stent graft coverage or length of
surgical graft replacement does not signiﬁcantly impact outcomes.
Outcomes of Open Surgical Repair for Chronic Type B Aortic
Dissections
Allan M. Conway, Mostafa Sadek, Yonni Pellet, Georgia Panagopoulos,
Alﬁo Carroccio, Konstadinos Plestis. Lenox Hill Heart and Vascular
Institute of New York, New York, NY
Objectives: Open surgical repair (OSR) for chronic type B aortic
dissections (CTBAD) has an associated morbidity and mortality. The role
of thoracic endovascular aneurysm repair (TEVAR) in CTBAD has not
been determined. We analyzed our contemporary experience of CTBAD
undergoing OSR to identify high-risk patients that may be considered for
TEVAR.
Methods: From 1999-2010, 221 patients had repair of descending
thoracic and thoracoabdominal aortic aneurysms, including 86 patients
with CTBAD. We analyzed this cohort for mortality, complications, length
of stay, and reinterventions.
Results: OSR was performed in 25 (29%) and 61 (71%) patients for
descending thoracic and thoracoabdominal CTBAD, respectively. Mean
age was 58.4 years (610.4) and mean diameter 6.2 cm (61.1, 4.1-10.0).
Fifty-nine (69%) patients were male. Eight (9%) were treated for rupture.
Mean duration of follow-up was 5.2 years (62.7). Hospital mortality
occurred in ﬁve (5.8%) patients. Cardiopulmonary bypass was used in 83
(97%) and deep hypothermic arrest in 36 (42%) patients. Paraplegia
occurred in two (2.3%), stroke in two (2.3%), and renal failure requiring
permanent hemodialysis in two (2.3%) patients. Average length of stay
was 19.6 days (617.8). Univariate predictor of hospital mortality included
redo-operations and prolonged pump time (P < .05). Maximum aneurysm
diameter and rupture at presentation trended toward signiﬁcance. Twenty
1160 Abstracts(24.7%) patients of the 81 survivors died during follow-up (mean, 62.5 6
36 months). Six patients (7%) had aortic related reoperations at a mean of
3.8 years (61.8): one for ascending and ﬁve for descending aortic aneu-
rysms. Overall survival at 1, 5, and 7 years was 92%, 83%, and 70%, respec-
tively. Freedom from reoperation was 99%, 90%, and 86%, respectively.
Conclusions: OSR of CTBAD is a durable option with low mortality.
Patients requiring redo-operations or anticipated prolonged pump time
need further evaluation to determine whether conventional OSR or
TEVAR, if feasible, is the optimal treatment option.
Outcomes for Ruptured AAA (REVAR And Open AAA Repair) Are
Favorable if Performed by Vascular Surgeons Compared with
General Surgeons
Faisal Aziz, Amy B. Reed. Penn State University, Hershey, Pa
Objectives: Open repair for ruptured AAA (ROAR) has been the
standard treatment. Vascular surgeons (VS) have pioneered REVAR over
past two decades. Gradually, general surgeons (GS) have also learned this
technique. The purpose of this study was to review the nationwide trends
among specialties preforming operations for rAAA and outcomes.
Methods: American College of Surgeons-National Surgical Quality
Improvement Program database was searched for surgeries performed
for rAAA during 2005-2009. Patients’ demographics and comorbidities
(diabetes mellitus, hypertension, chronic obstructive pulmonary disease,
congestive heart failure, myocardial infarction, dialysis dependency, periph-
eral artery disease) were collected. Operations performed by VS and GS
were identiﬁed. We also collected American Society of Anesthesiologists
scores, operating times, lengths of hospital stay, postop complications and
mortality.
Results: A total of 1354 patients were identiﬁed. Mean age, 71 years,
82% male. Comorbidities: diabetes mellitus (14%), smoking (43%), chronic
obstructive pulmonary disease (18%), congestive heart failure (14%),
myocardial infarction (1.4%), hypertension (75%), dialysis (1%), and periph-
eral artery disease (6%). ROAR was performed in 978 (72%) and REVAR in
376 (28%) patients. Average operating time: 194 minutes (ROAR) vs 177
minutes (REVAR). GS performed 0% of REVARs in 2005, which increased
to 6% in 2009. Mortality of REVAR was 26% (VS) and 59% (GS) (P ¼
.021); mortality for ROAR was 36% (VS) and 52% (GS) (P ¼ .019)
(Fig). The average operating times (minutes) for REVAR were 178 (VS)
and 205 (GS); for ROAR they were 190 (VS) and 200 (GS).
Conclusions: Vascular surgeons established REVAR as a standard
therapy but are gradually performing less of it, which may reﬂect the
increasing level of comfort of general surgeons. Thirty-day mortality is
favorable if VS perform the operation.
Fig.
